Literature DB >> 1369487

Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor.

W Wels1, I M Harwerth, M Zwickl, N Hardman, B Groner, N E Hynes.   

Abstract

We have constructed genes expressing single-chain antigen binding proteins (scFv) which recognize the human erbB-2 receptor. These genes encode the heavy and light chain variable domains of an erbB-2 receptor specific monoclonal antibody, MAb FRP5, connected by a peptide linker. In order to express a bifunctional molecule, a bacterial alkaline phosphatase gene was fused 3' to the scFv gene. The scFv(FRP5) and scFv(FRP5)-alkaline phosphatase fusion protein (scFv(FRP5)-PhoA) expressed in E. coli specifically recognize the human erbB-2 protein and compete with MAb FRP5 for binding to the receptor. The bound scFv(FRP5)-PhoA protein can be detected directly on tumor cells using a substrate for alkaline phosphatase, showing that the chimeric protein retains both binding and enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1369487     DOI: 10.1038/nbt1092-1128

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  28 in total

1.  Drop-out phagemid vector for switching from phage displayed affinity reagents to expression formats.

Authors:  Kritika Pershad; Mark A Sullivan; Brian K Kay
Journal:  Anal Biochem       Date:  2011-03-01       Impact factor: 3.365

2.  One-step immunoassay for tetrabromobisphenol a using a camelid single domain antibody-alkaline phosphatase fusion protein.

Authors:  Jia Wang; Zuzana Majkova; Candace R S Bever; Jun Yang; Shirley J Gee; Ji Li; Ting Xu; Bruce D Hammock
Journal:  Anal Chem       Date:  2015-04-22       Impact factor: 6.986

3.  T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.

Authors:  Simone Krebs; Kevin K H Chow; Zhongzhen Yi; Tania Rodriguez-Cruz; Meenakshi Hegde; Claudia Gerken; Nabil Ahmed; Stephen Gottschalk
Journal:  Cytotherapy       Date:  2014-05-16       Impact factor: 5.414

Review 4.  Engineering recombinant antibodies for immunotherapy.

Authors:  D Neri; H Petrul; G Roncucci
Journal:  Cell Biophys       Date:  1995-08

5.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Authors:  Kurt Schönfeld; Christiane Sahm; Congcong Zhang; Sonja Naundorf; Christian Brendel; Marcus Odendahl; Paulina Nowakowska; Halvard Bönig; Ulrike Köhl; Stephan Kloess; Sylvia Köhler; Heidi Holtgreve-Grez; Anna Jauch; Manfred Schmidt; Ralf Schubert; Klaus Kühlcke; Erhard Seifried; Hans G Klingemann; Michael A Rieger; Torsten Tonn; Manuel Grez; Winfried S Wels
Journal:  Mol Ther       Date:  2014-11-06       Impact factor: 11.454

6.  T cells redirected to EphA2 for the immunotherapy of glioblastoma.

Authors:  Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

Review 7.  Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies.

Authors:  R R Beerli; W Wels; N E Hynes
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Authors:  R R Beerli; D Graus-Porta; K Woods-Cook; X Chen; Y Yarden; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

9.  Construction and expression of a bifunctional single-chain antibody against Bacillus cereus p6ores.

Authors:  K Koo; P M Foegeding; H E Swaisgood
Journal:  Appl Environ Microbiol       Date:  1998-07       Impact factor: 4.792

10.  Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.

Authors:  D Moritz; W Wels; J Mattern; B Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.